HOME >> BIOLOGY >> NEWS
Chernobyl study: Risk of thyroid cancer rises with radiation dose

t and supplies, and then figuring out a way to maintain them without the standard resources that one takes for granted in the United States.

"It's been a long haul and an enormous amount of time and work," Davis said, whose 30-plus trips to the former Soviet Union include walking the grounds of the evacuated plant and surveying the desolated 30-kilometer evacuation zone.

Once the team established the capability to do the research, the group began its studies of thyroid cancer, a disease linked to radiation exposure. By the early 1990s, many new cases of the disease, particularly among young children, were diagnosed in regions near the blast. Since then, reports show several hundred cases of thyroid cancer in young children in the three countries contaminated by Chernobyl, a trend that appears to be continuing.

Despite the lack of resources available to initiate these studies, Davis said that scientists and citizens of the three countries were eager for the research from the start. "Our collaborators in Russia have been terrific colleagues," he said. "We now have very close ties with our partner institutions."

He also credited the strong encouragement and support from Fred Hutchinson's senior administration for helping him establish stable working relationships with their overseas colleagues.

"The incredible support and flexibility of the center, especially in the early stages, really made this happen. That can't be overstated," Davis said.


'"/>

Contact: Kristen Lidke Woodward
kwoodwar@fhcrc.org
206-667-5095
Fred Hutchinson Cancer Research Center
1-Sep-2004


Page: 1 2 3 4 5 6

Related biology news :

1. Amorous worms reveal effects of Chernobyl
2. Echinacea Symposium Presents New Research On Chernobyl Victims
3. United States And Ukrainian Governments Establish Permanent Chernobyl Laboratory
4. UW study: Migrating birds offer insight into sleep
5. UF study: Barren Siberia, of all places, may be original home to animal life
6. Comprehensive study: We know little about environmental effects on kids
7. UW study: Babys face lights up emotional center of new moms brain
8. UF study: World shark attacks sink again, may signal long-term trend
9. Fox Chase Cancer Center study: Novel DNA-repair gene mutation can cause resistance to cancer drugs
10. New study: percentage of babies born with intestinal birth defect growing in U.S., N.C.
11. MIT study: Hydrogen car no environmental panacea

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Chernobyl study Risk thyroid cancer rises with radiation dose

(Date:11/18/2014)... BOSTON , Nov. 17, 2014   ... HealthCare and EMC collaborate to develop The Partners ... , The Partners Data Lake will allow ... to improve diagnostics, treatment and the lives of ... support research and clinical activities across the Partners ...
(Date:11/18/2014)... YORK , Nov. 18, 2014   ... identity authentication solutions, and MorphoTrust USA ... and services, today announced a strategic partnership to ... enterprise, motor vehicle administration (MVA), airport screening and ... in identity-related solutions, MorphoTrust serves consumers through a ...
(Date:11/12/2014)... , Nov. 12, 2014 Crossmatch™, a leading ... its U.are.U ® fingerprint readers have been deployed ... Central Mexico . The bakery chain ... eliminate payroll issues caused by employees clocking in for ... U.are.U fingerprint readers, Montparnasse relied on paper timecards and ...
Breaking Biology News(10 mins):Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2
(Date:12/19/2014)... iLab Solutions, the global leader in ... Bryant as the new Director of Institutional Implementations and ... These two new leadership positions were created to support ... that iLab continues to meet the needs of its ... iLab has been deployed at over 450 core facilities ...
(Date:12/19/2014)... Dec. 18, 2014  Decision Resources Group finds that ... market will grow moderately through 2023 as the aging ... awareness of dental biomaterials all spur procedure volumes. Growth ... China and India ... procedures within reach for a larger proportion of the ...
(Date:12/17/2014)... 2014 The Activated Carbon Manufacturing ... is why IBISWorld updated its original industry research report. ... from an intensified focus on environmental policy. Over the ... standards for power plants and a range of other ... Industry Analyst Sarah Kahn, “a range of downstream industrial ...
(Date:12/17/2014)... 17, 2014 Ipsen Biopharmaceuticals, Inc., ... ADR: IPSEY), today announced that Somatuline® ... Somatuline®) was approved by the U.S. Food and ... neuroendocrine tumors (GEP-NETs) in adult patients with unresectable, ... disease to improve progression-free survival (PFS). , “The ...
Breaking Biology Technology:iLab Solutions Announces Two New Leadership Positions to Meet the Needs of Its Growing Customer Base 2Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 2Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 3Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 2Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8
Cached News: